Global Markets Direct’s, ‘Moderate Psoriasis – Pipeline Review, H2 2015′, provides an overview of the Moderate Psoriasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Moderate Psoriasis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Moderate Psoriasis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Moderate Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Moderate Psoriasis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Moderate Psoriasis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Moderate Psoriasis Overview 10
Therapeutics Development 11
Pipeline Products for Moderate Psoriasis - Overview 11
Moderate Psoriasis - Therapeutics under Development by Companies 12
Moderate Psoriasis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Moderate Psoriasis - Products under Development by Companies 17
Moderate Psoriasis - Companies Involved in Therapeutics Development 19
AbGenomics International, Inc. 19
ADC Therapeutics Sarl 20
Almirall, S.A. 21
AstraZeneca Plc 22
Avexxin AS 23
Boehringer Ingelheim GmbH 24
Celgene Corporation 25
Convoy Therapeutics, Inc. 26
Crescendo Biologics Limited 27
Delenex Therapeutics AG 28
Eli Lilly and Company 29
Forward Pharma A/S 30
Galectin Therapeutics, Inc. 31
GlycoMar Limited 32
Idera Pharmaceuticals, Inc. 33
Johnson & Johnson 34
Merck KGaA 35
OPKO Health, Inc. 36
Sandoz International GmbH 37
Soligenix, Inc. 38
Sun Pharma Advanced Research Company Ltd. 39
Syntrix Biosystems, Inc. 40
Valeant Pharmaceuticals International, Inc. 41
Moderate Psoriasis - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
(halobetasol propionate + tazarotene) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AbGn-168H - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
adalimumab biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AKP-11 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
aminopterin sodium - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AVX-001 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
baricitinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BI-655066 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
brodalumab - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CB-001 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CC-90005 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
COVA-322 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
cyclosporine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
dimethyl fumarate - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
dimethyl fumarate - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DLX-105 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
etanercept biosimilar - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
etanercept biosimilar - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
GLY-2028 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
GRMD-02 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
guselkumab - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
IMO-8400 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
ixekizumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
lunacalcipol - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
M-1095 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
orilotimod potassium - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SGX-301 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
tazarotene - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
tildrakizumab - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
toreforant tartrate - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
VM-101 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Moderate Psoriasis - Recent Pipeline Updates 98
Moderate Psoriasis - Dormant Projects 131
Moderate Psoriasis - Discontinued Products 132
Moderate Psoriasis - Product Development Milestones 133
Featured News & Press Releases 133
Sep 11, 2014: Delenex Announces New Clinical Data 133
Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 133
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 135
Disclaimer 136

List of Tables

Number of Products under Development for Moderate Psoriasis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Products under Development by Companies, H2 2015 (Contd..1) 18
Moderate Psoriasis - Pipeline by AbGenomics International, Inc., H2 2015 19
Moderate Psoriasis - Pipeline by ADC Therapeutics Sarl, H2 2015 20
Moderate Psoriasis - Pipeline by Almirall, S.A., H2 2015 21
Moderate Psoriasis - Pipeline by AstraZeneca Plc, H2 2015 22
Moderate Psoriasis - Pipeline by Avexxin AS, H2 2015 23
Moderate Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2015 24
Moderate Psoriasis - Pipeline by Celgene Corporation, H2 2015 25
Moderate Psoriasis - Pipeline by Convoy Therapeutics, Inc., H2 2015 26
Moderate Psoriasis - Pipeline by Crescendo Biologics Limited, H2 2015 27
Moderate Psoriasis - Pipeline by Delenex Therapeutics AG, H2 2015 28
Moderate Psoriasis - Pipeline by Eli Lilly and Company, H2 2015 29
Moderate Psoriasis - Pipeline by Forward Pharma A/S, H2 2015 30
Moderate Psoriasis - Pipeline by Galectin Therapeutics, Inc., H2 2015 31
Moderate Psoriasis - Pipeline by GlycoMar Limited, H2 2015 32
Moderate Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2015 33
Moderate Psoriasis - Pipeline by Johnson & Johnson, H2 2015 34
Moderate Psoriasis - Pipeline by Merck KGaA, H2 2015 35
Moderate Psoriasis - Pipeline by OPKO Health, Inc., H2 2015 36
Moderate Psoriasis - Pipeline by Sandoz International GmbH, H2 2015 37
Moderate Psoriasis - Pipeline by Soligenix, Inc., H2 2015 38
Moderate Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 39
Moderate Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2015 40
Moderate Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015 41
Assessment by Monotherapy Products, H2 2015 42
Assessment by Combination Products, H2 2015 43
Number of Products by Stage and Target, H2 2015 45
Number of Products by Stage and Mechanism of Action, H2 2015 48
Number of Products by Stage and Route of Administration, H2 2015 50
Number of Products by Stage and Molecule Type, H2 2015 52
Moderate Psoriasis Therapeutics - Recent Pipeline Updates, H2 2015 98
Moderate Psoriasis - Dormant Projects, H2 2015 131
Moderate Psoriasis - Discontinued Products, H2 2015 132

List of Figures

Number of Products under Development for Moderate Psoriasis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Products, H2 2015 16
Assessment by Monotherapy Products, H2 2015 42
Number of Products by Top 10 Targets, H2 2015 44
Number of Products by Stage and Top 10 Targets, H2 2015 44
Number of Products by Top 10 Mechanism of Actions, H2 2015 47
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 47
Number of Products by Routes of Administration, H2 2015 49
Number of Products by Stage and Routes of Administration, H2 2015 49
Number of Products by Molecule Types, H2 2015 51
Number of Products by Stage and Molecule Types, H2 2015 51